SkinHealth Systems Reports Q1 Sales Decline, Narrows Net Loss, Lowers Full-Year Revenue Guidance
SKIN is trading near its 52-week low of $0.757 (9.6% above the low) on elevated volume (3.5× avg).
Summary
SkinHealth Systems reported a 6.7% decline in Q1 net sales to $64.9 million, but narrowed its net loss and improved adjusted EBITDA. The company also lowered its full-year 2026 revenue guidance, signaling continued market challenges.
Key Events · Earnings and Guidance · SKIN
-
Q1 2026 Net Sales Decline
Net sales for the first quarter of 2026 were $64.9 million, a 6.7% decrease compared to $69.6 million in the prior year period, primarily due to lower delivery systems and consumables net sales.
-
Improved Profitability Metrics
The company narrowed its net loss to $(6.6) million from $(10.1) million in Q1 2025 and increased Adjusted EBITDA to $8.5 million from $7.3 million, driven by lower operational spend.
-
Lowered Full-Year Revenue Guidance
SkinHealth Systems revised its full-year 2026 net sales guidance downwards to a range of $280 – $295 million, reflecting continued pressure on year-over-year device sales.
-
Operational Performance
The company placed 746 delivery systems in Q1 2026, down from 862 in Q1 2025, though the active install base grew to 36,419 from 35,014.
Analysis · SKIN · Industrial Applications And Services
SkinHealth Systems reported a mixed first quarter, with net sales declining by 6.7% year-over-year to $64.9 million, and a reduction in delivery systems sold. This top-line weakness is further underscored by the company's decision to lower its full-year 2026 net sales guidance to $280 – $295 million. While the company demonstrated improved operational efficiency by narrowing its net loss and increasing adjusted EBITDA, the reduced revenue outlook and continued pressure on device sales present a significant challenge. This earnings report follows closely on the heels of the Chief Revenue Officer's termination, suggesting the company is actively addressing performance issues. Investors will be watching for signs of stabilization in sales and the effectiveness of new execution strategies.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SKIN was trading at $0.83 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $117.9M. The 52-week trading range was $0.76 to $2.69. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.